{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:18:35Z","timestamp":1792084715693,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.expneurol.2004.02.005","type":"journal-article","created":{"date-parts":[[2004,3,28]],"date-time":"2004-03-28T19:36:12Z","timestamp":1080502572000},"page":"279-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores"],"prefix":"10.1016","volume":"188","author":[{"given":"Paul A.","family":"Lapchak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Zivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2004.02.005_BIB1","doi-asserted-by":"crossref","first-page":"29D","DOI":"10.1016\/S0002-9149(97)00582-1","article-title":"Hyperacute stroke therapy with tissue plasminogen activator","volume":"80","author":"Alberts","year":"1997","journal-title":"Am. J. Cardiol"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0002-9343(98)00414-8","article-title":"Diagnosis and treatment of ischemic stroke","volume":"106","author":"Alberts","year":"1999","journal-title":"Am. J. Med"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00004647-200003000-00002","article-title":"Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats","volume":"20","author":"Asahi","year":"2000","journal-title":"J. Cereb. Blood Flow Metab"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0166-2236(99)01401-0","article-title":"Pathobiology of ischaemic stroke: an integrated view","volume":"22","author":"Dirnagl","year":"1999","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB5","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1046\/j.1440-1681.2002.03767.x","article-title":"Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective","volume":"29","author":"Green","year":"2002","journal-title":"Clin. Exp. Pharmacol. Physiol"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB6","first-page":"37","article-title":"Stroke\u2014Acute interventions","volume":"63","author":"Heiss","year":"2002","journal-title":"J. Neural Transm., Suppl"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00004647-199907000-00008","article-title":"Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat","volume":"19","author":"Kuroda","year":"1999","journal-title":"J. Cereb. Blood Flow Metab"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1517\/13543784.11.11.1623","article-title":"Development of thrombolytic therapy for stroke: a perspective","volume":"11","author":"Lapchak","year":"2002","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB9","first-page":"1758","article-title":"NXY-059. Centaur","volume":"3","author":"Lapchak","year":"2002","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00023210-200115110-00001","article-title":"Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents","volume":"15","author":"Lapchak","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1527-3458.2003.tb00252.x","article-title":"Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke","volume":"9","author":"Lapchak","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB12","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1161\/01.STR.0000081223.74129.04","article-title":"Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator","volume":"34","author":"Lapchak","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB13","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1161\/01.STR.0000028267.09604.7B","article-title":"Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits","volume":"33","author":"Lapchak","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB14","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1161\/01.STR.0000017145.22806.AA","article-title":"Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: combination studies with tissue plasminogen activator","volume":"33","author":"Lapchak","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB15","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.STR.0000015346.00054.8B","article-title":"Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator","volume":"33","author":"Lapchak","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2003.09.009","article-title":"Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits","volume":"185","author":"Lapchak","year":"2004","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00023210-200115030-00001","article-title":"Neuroprotection for ischaemic stroke: an unattainable goal?","volume":"15","author":"Liebeskind","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/10715760100300351","article-title":"Comparison of the radical trapping ability of PBN, S-PBN and NXY-059","volume":"34","author":"Maples","year":"2001","journal-title":"Free Radical Res"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1161\/01.STR.32.1.190","article-title":"NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species","volume":"32","author":"Marshall","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB20","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1161\/01.STR.0000087790.79851.A8","article-title":"Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion","volume":"34","author":"Marshall","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0006-8993(03)02511-3","article-title":"Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures","volume":"972","author":"Marshall","year":"2003","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB22","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/01.STR.0000018684.86293.AB","article-title":"Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design","volume":"33","author":"Muir","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11910-003-0031-z","article-title":"Neuroprotective agents for the treatment of acute ischemic stroke","volume":"3","author":"Ovbiagele","year":"2003","journal-title":"Curr. Neurol. Neurosci. Rep"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB33","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1161\/01.STR.30.12.2752","article-title":"Recommendations for standards regarding preclinical neuroprotective and restorative drug development","volume":"30","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.bjp.0704449","article-title":"Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window","volume":"135","author":"Sydserff","year":"2002","journal-title":"Br. J. Pharmacol"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2169\/internalmedicine.41.337","article-title":"Treatment of acute ischemic stroke: recent progress","volume":"41","author":"Tanahashi","year":"2002","journal-title":"Intern. Med"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(97)03022-5","article-title":"Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke","volume":"350","author":"Wardlaw","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0006-8993(02)02286-2","article-title":"Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A","volume":"932","author":"Yoshimoto","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0006-8993(00)02693-7","article-title":"Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat","volume":"878","author":"Zhang","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0006-8993(01)02618-X","article-title":"NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat","volume":"909","author":"Zhao","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1212\/WNL.53.1.14","article-title":"Thrombolytic stroke therapy: past, present, and future","volume":"53","author":"Zivin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB31","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/01.STR.23.5.767","article-title":"Quantal bioassay and stroke","volume":"23","author":"Zivin","year":"1992","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2004.02.005_BIB32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.1988.00520280033012","article-title":"Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke","volume":"45","author":"Zivin","year":"1988","journal-title":"Arch. Neurol"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488604000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488604000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:41:00Z","timestamp":1762148460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488604000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0014488604000597"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2004.02.005","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2004.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}